Chondroitin Sulfate

Active pharmaceutical ingredient for the symptomatic treatment of osteoarthritis and joint discomfort

Bioiberica's Chondroitin Sulfate API is a high-quality, animal-derived ingredient for the development of finished pharmaceutical formulations targeting osteoarthritis and joint discomfort.

As a world-reference in animal-derived APIs, our pharmaceutical grade chondroitin sulfate is **manufactured in Europe under strict GMP quality standards** and complies with US and EU Pharmacopoeias. We also offer the **technical support and regulatory expertise** manufacturers need to bring their products to market faster and with enduring success.

As individuals age, the cartilage begins to wear down, resulting in the onset of degenerative joint diseases, like osteoarthritis. Chondroitin sulfate is proven to slow this process[1], and is therefore commonly prescribed as a Symptomatic Slow Acting Drug for the symptomatic treatment of knee and hip osteoarthritis.

About chondroitin sulfate

Chondroitin sulfate is a sulfated glycosaminoglycan (GAG), composed of a chain of alternating sugars: N-acetylgalactosamine and glucuronic acid. It is found in the extracellular matrix (ECM) of connective tissues, cartilage and tendons, where it acts as an important structural component and provides much of the ECM's resistance and compression capabilities.

Chondroitin sulfate is recommended by national and international therapeutic guidelines, with clinical trials demonstrating its effectiveness in reducing joint pain and improving mobility.[2,3]

Features and overview

- Suitable for oral and injectable pharmaceuticals and medical devices
- DMF available on demand
- Recommended dosage: 800-1,200 mg daily

Origins available: Bovine and porcine

Physical appearance: White or almost white hygroscopic powder

Purity: 95-105%

Sample size: 75 g

MOQ: 150 kg

Retest: 4 years

Packaging: 25 kg double bag in kraft drum for oral chondroitin sulfate or 25 kg triple bag in metal drum for injectable chondroitin sulfate

Storage: Room temperature

Pharmacopoeia: Europe, United States, Japan, Korea and Russia

Certificates

- GMP certificate for APIs
- EDQM certificates of Suitability (double and TSE CEPs)
- Accreditation of foreign drug manufacturer (AFM, Japan)
- KFDA registration (Korea)
- TFDA registration (Taiwan)
- Normative Documentation (ND, Russia)

Your partner for taking healthcare further

We are your trusted partner for growth and innovation in the healthcare market.

In addition to our specialisation in animal-derived molecules, our production capacity and vertically integrated model guarantees full traceability, security of supply and sustainability. Our commitment to international standards and industrial excellence provides peace of mind that our APIs are manufactured to the highest quality, safety and regulatory standards.

European manufacturer:

- Reference in animal-derived APIs
- GMPs
- Derived from animals declared fit for human consumption

Extensive product support:

- Quality & technical support
- Regulatory support
- Market experience

Reliable supply:

- Highest safety standards
- Vertical Integration
- Price & supply stability

About Bioiberica

Bioiberica is a global Life Science company with more than 45 years of experience in the identification, extraction and development of molecules of high biological and therapeutic value for the pharmaceutical and nutraceutical industries.

This specialisation positions Bioiberica among the leading Heparin API manufacturers and as a world reference in the research, production and sale of other animal-derived APIs and ingredients, such as thyroid, chondroitin sulfate, glucosamine, native type II collagen and hyaluronic acid.

To accelerate healthcare developments and support patients worldwide using Bioiberica's Chondroitin Sulfate API, contact us today.

Visit: **www.bioiberica.com** Email: **healthcare@bioiberica.com** Call: **+34 93 490 49 08**

Chondroitin Sulfate

Bioiberica
Taking life science further

Y500100/0721

1) Pelletier JP, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016 Nov 3;18(1):256.
2) Bruyère O, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-350.
3) Rillo O, et al. PANLAR Consensus Recommendations for the Management in Osteoarthritis of Hand, Hip, and Knee. J Clin Rheumatol. 2016 Oct;22(7):345-54.